AM

Ashokan Murugan

Active Director Director DIN 06651206
DIN 06651206 First appointment Sep 2013 Primary industry Chemicals
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Sep 2013
Shareholding value •••• Premium profile

About Ashokan Murugan

Data last updated:

Ashokan Murugan is a Director at Synchroz Pharmaceuticals Private Limited (since 2013). The company operates in Chemicals. Synchroz Pharmaceuticals Private Limited reported revenue of ₹72.6 Lakh (FY 2024).

DIN 06651206
Primary Designation Director
Industry Chemicals
First Appointment 06 Sep 2013
Oldest Company Age 13 yrs
Largest company Synchroz Pharmaceuticals Private Limited · ₹72.6 Lakh (FY 2024)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director06 Sep 20132013₹72.6 Lakh (FY 2024)Active

Board colleagues of Ashokan Murugan

Directorship timeline

Open interactive timeline →
Synchroz Pharmaceuticals Private Limited
Premium access

Shareholding and investment profile for Ashokan Murugan

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Ashokan Murugan

Ashokan Murugan currently holds 1 directorship: Synchroz Pharmaceuticals Private Limited (Director, since 06 Sep 2013, revenue ₹72.6 Lakh (FY 2024)).

Ashokan Murugan was first appointed on 06 Sep 2013 as Director at Synchroz Pharmaceuticals Private Limited.

The current boards of Ashokan Murugan's companies include Mutham Perumal Sumathi Nadarajan (Synchroz Pharmaceuticals Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available